| 11/17/2026 4:29 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/16/2026 3:30 PM | Entero Therapeutics (1604191) Filer | Form PRE 14A | |
| 10/30/2026 4:03 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/28/2026 8:51 PM | BORKOWSKI EDWARD (1197542) Reporting Entero Therapeutics (1604191) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2026 8:52 PM | Entero Therapeutics (1604191) Issuer Pursglove Geordan Garrett (2073519) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2026 8:53 PM | Entero Therapeutics (1604191) Issuer Sawyer Jason David (2076325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2026 8:54 PM | Entero Therapeutics (1604191) Issuer Skowron Anna (2066250) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2026 8:56 PM | Entero Therapeutics (1604191) Issuer Syage Jack (2014106) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2026 8:57 PM | Entero Therapeutics (1604191) Issuer Uppal Manpreet (2056422) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/28/2026 4:00 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/28/2026 3:16 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for GRDX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 10/28/2026 5:03 AM | Entero Therapeutics (1604191) Filer | Form POS AM | |
| 10/26/2026 7:02 PM | Entero Therapeutics (1604191) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 10/23/2026 4:00 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/19/2026 11:15 PM | Entero Therapeutics (1604191) Filer | Form EFFECT | |
| 10/19/2026 4:20 PM | Entero Therapeutics (1604191) Filer | Form 424B3 | |
| 10/09/2026 5:31 PM | Entero Therapeutics (1604191) Issuer Sawyer Jason David (2076325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/07/2026 3:01 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/06/2026 3:27 PM | Entero Therapeutics (1604191) Filer | Form S-1/A | |
| 09/11/2026 3:43 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/24/2026 2:33 PM | Entero Therapeutics (1604191) Filer | Form S-1/A | |
| 08/21/2026 4:26 PM | Entero Therapeutics (1604191) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2026 3:04 PM | Entero Therapeutics (1604191) Filer | Form S-1/A | |
| 07/15/2026 3:00 PM | Entero Therapeutics (1604191) Filer | Form D Notice of Exempt Offering of Securities | |
| 07/09/2026 4:25 PM | Entero Therapeutics (1604191) Filer | Form S-1/A | |
| 07/08/2026 3:05 PM | Entero Therapeutics (1604191) Subject Sawyer Jason David (2076325) Filed by | Form SCHEDULE 13D | |
| 07/07/2026 3:58 PM | Entero Therapeutics (1604191) Filer | Form 8-K/A | |
| 07/06/2026 4:23 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/01/2026 7:48 PM | Entero Therapeutics (1604191) Issuer Sawyer Jason David (2076325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/04/2026 2:48 PM | Entero Therapeutics (1604191) Filer | Form POS AM | |
| 06/03/2026 7:11 PM | Entero Therapeutics (1604191) Issuer Syage Jack (2014106) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/27/2026 5:04 AM | Entero Therapeutics (1604191) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/20/2026 3:06 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/01/2026 3:02 PM | Entero Therapeutics (1604191) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 04/28/2026 4:25 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/24/2026 3:04 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/13/2026 5:01 AM | Entero Therapeutics (1604191) Filer | Form 8-K/A | |
| 03/16/2026 8:23 PM | Entero Therapeutics (1604191) Filer | Form RW | |
| 02/12/2026 1:14 PM | Entero Therapeutics (1604191) Subject RENAISSANCE TECHNOLOGIES LLC (1037389) Filed by | Form SCHEDULE 13G/A | |
| 01/13/2026 1:13 PM | Entero Therapeutics (1604191) Subject Strategic EP, LLC (2081874) Filed by | Form SCHEDULE 13G | |
| 01/08/2026 4:28 PM | BORKOWSKI EDWARD (1197542) Reporting Entero Therapeutics (1604191) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Earn $4,500 a month? Your income may count for more (Ad) Earn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score.
Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score.
Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed. Check your personal loan rate with Pennie in about two minutes with no fee |
| 01/07/2026 3:05 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 4:24 PM | Entero Therapeutics (1604191) Issuer Uppal Manpreet (2056422) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 4:59 PM | Entero Therapeutics (1604191) Issuer Sawyer Jason David (2076325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 4:31 PM | Entero Therapeutics (1604191) Issuer Skowron Anna (2066250) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 12/29/2025 4:32 PM | Entero Therapeutics (1604191) Issuer Skowron Anna (2066250) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/23/2025 3:10 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/04/2025 4:21 PM | Entero Therapeutics (1604191) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |